دورية أكاديمية
أعرض في EDS

Hippo Signaling Pathway Dysregulation in Human Huntington's Disease Brain and Neuronal Stem Cells.

التفاصيل البيبلوغرافية
العنوان: Hippo Signaling Pathway Dysregulation in Human Huntington's Disease Brain and Neuronal Stem Cells.
المؤلفون: Mueller KA; NeuroEpigenetics Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Glajch KE; NeuroEpigenetics Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Huizenga MN; NeuroEpigenetics Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Wilson RA; NeuroEpigenetics Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Granucci EJ; NeuroEpigenetics Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Dios AM; NeuroEpigenetics Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Tousley AR; Cellular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Iuliano M; Cellular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Weisman E; Cellular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., LaQuaglia MJ; Department of Surgery, Boston Children's Hospital, Boston, USA., DiFiglia M; Cellular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Kegel-Gleason K; Cellular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA., Vakili K; Department of Surgery, Boston Children's Hospital, Boston, USA., Sadri-Vakili G; NeuroEpigenetics Laboratory, MassGeneral Institute for Neurodegenerative Disease (MIND), Massachusetts General Hospital, Boston, MA, 02129-4404, USA. gsadrivakili@mgh.harvard.edu.
المصدر: Scientific reports [Sci Rep] 2018 Jul 27; Vol. 8 (1), pp. 11355. Date of Electronic Publication: 2018 Jul 27.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Signal Transduction*, Brain/*pathology , Huntington Disease/*metabolism , Huntington Disease/*pathology , Neural Stem Cells/*metabolism , Protein Serine-Threonine Kinases/*metabolism, 14-3-3 Proteins/metabolism ; Adaptor Proteins, Signal Transducing/genetics ; Adaptor Proteins, Signal Transducing/metabolism ; Animals ; Disease Models, Animal ; Hippo Signaling Pathway ; Humans ; Neural Stem Cells/pathology ; Phosphoproteins/genetics ; Phosphoproteins/metabolism ; Phosphorylation ; Protein Binding ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Transcription Factors ; Transcription, Genetic ; YAP-Signaling Proteins
مستخلص: The Hippo signaling pathway is involved in organ size regulation and tumor suppression. Although inhibition of Hippo leads to tumorigenesis, activation of Hippo may play a role in neurodegeneration. Specifically, activation of the upstream regulator, mammalian sterile 20 (STE20)-like kinase 1 (MST1), reduces activity of the transcriptional co-activator Yes-Associated Protein (YAP), thereby mediating oxidative stress-induced neuronal death. Here, we investigated the possible role of this pathway in Huntington's disease (HD) pathogenesis. Our results demonstrate a significant increase in phosphorylated MST1, the active form, in post-mortem HD cortex and in the brains of CAG knock-in Hdh Q111/Q111 mice. YAP nuclear localization was also decreased in HD post-mortem cortex and in neuronal stem cells derived from HD patients. Moreover, there was a significant increase in phosphorylated YAP, the inactive form, in HD post-mortem cortex and in Hdh Q111/Q111 brain. In addition, YAP was found to interact with huntingtin (Htt) and the chaperone 14-3-3, however this interaction was not altered in the presence of mutant Htt. Lastly, YAP/TEAD interactions and expression of Hippo pathway genes were altered in HD. Together, these results demonstrate that activation of MST1 together with a decrease in nuclear YAP could significantly contribute to transcriptional dysregulation in HD.
References: Oncogene. 2005 Jun 16;24(26):4232-42. (PMID: 15824737)
J Med Chem. 2015 Jun 25;58(12):4857-73. (PMID: 25719868)
Med Hypotheses. 2006;67(1):169-71. (PMID: 16516399)
Ann Neurol. 1997 Aug;42(2):215-21. (PMID: 9266732)
Hum Mol Genet. 2000 May 22;9(9):1259-71. (PMID: 10814708)
Nat Rev Neurosci. 2003 Sep;4(9):752-62. (PMID: 12951567)
J Hepatol. 2015 Dec;63(6):1491-501. (PMID: 26226451)
J Neurol. 2006 Sep;253(9):1137-42. (PMID: 16998646)
Curr Biol. 2007 Dec 4;17(23):2054-60. (PMID: 17980593)
J Neurosci. 2010 Sep 1;30(35):11735-44. (PMID: 20810894)
Am J Physiol Gastrointest Liver Physiol. 2014 Jul 15;307(2):G196-204. (PMID: 24875096)
Mol Cell Biol. 2008 Apr;28(7):2426-36. (PMID: 18227151)
J Clin Oncol. 2006 Nov 20;24(33):5223-33. (PMID: 17114655)
Lancet Neurol. 2011 Jan;10(1):83-98. (PMID: 21163446)
Cell Death Dis. 2013 May 09;4:e625. (PMID: 23661003)
Neuron. 1995 May;14(5):1075-81. (PMID: 7748555)
Sci STKE. 2003 Nov 04;2003(207):pe48. (PMID: 14600292)
Hum Mol Genet. 2007 Jun 1;16(11):1293-306. (PMID: 17409194)
Development. 2008 Mar;135(6):1081-8. (PMID: 18256197)
Neuron. 2012 Jul 12;75(1):41-57. (PMID: 22794259)
Nat Med. 2000 Jul;6(7):797-801. (PMID: 10888929)
Genes Dev. 2016 Jan 1;30(1):1-17. (PMID: 26728553)
Lancet Oncol. 2012 Jun;13(6):642-8. (PMID: 22503213)
Genes Dev. 2012 Jun 15;26(12):1300-5. (PMID: 22677547)
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6480-5. (PMID: 9600992)
Am J Cancer Res. 2015 Dec 15;6(1):27-37. (PMID: 27073720)
J Huntingtons Dis. 2015;4(1):1-15. (PMID: 25813218)
Cancer. 1999 Oct 1;86(7):1342-6. (PMID: 10506723)
Ann Neurol. 1996 Jul;40(1):49-54. (PMID: 8687191)
Hum Mol Genet. 2002 Aug 15;11(17):1911-26. (PMID: 12165554)
Genes Dev. 2009 Dec 1;23(23):2729-41. (PMID: 19952108)
Genes Dev. 2008 Jul 15;22(14):1962-71. (PMID: 18579750)
Gastroenterology. 2014 Sep;147(3):690-701. (PMID: 24837480)
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11023-8. (PMID: 16043692)
Hum Mol Genet. 2016 Nov 1;25(21):4749-4770. (PMID: 28171658)
Neurobiol Dis. 2012 May;46(2):351-61. (PMID: 22590724)
Hum Mol Genet. 1999 Jan;8(1):115-22. (PMID: 9887339)
Handb Clin Neurol. 2011;100:25-81. (PMID: 21496570)
Development. 2011 Jan;138(1):9-22. (PMID: 21138973)
Trends Neurosci. 2000 Sep;23(9):387-92. (PMID: 10941183)
J Cell Biol. 2006 Feb 13;172(4):589-604. (PMID: 16461361)
J Cell Sci. 2004 Apr 15;117(Pt 10):1875-84. (PMID: 15090593)
Genes Dev. 2001 May 15;15(10):1229-41. (PMID: 11358867)
N Engl J Med. 2003 Apr 3;348(14):1365-75. (PMID: 12672865)
Cell. 1993 Mar 26;72(6):971-83. (PMID: 8458085)
Cell. 2007 Sep 21;130(6):1120-33. (PMID: 17889654)
Neurobiol Dis. 2003 Dec;14(3):624-36. (PMID: 14678777)
Neuron. 2017 Apr 5;94(1):48-57.e4. (PMID: 28384474)
Mol Cell Neurosci. 2012 May;50(1):70-81. (PMID: 22508027)
Hum Mol Genet. 2006 Mar 15;15(6):965-77. (PMID: 16467349)
Trends Genet. 2003 May;19(5):233-8. (PMID: 12711212)
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12066-71. (PMID: 23818595)
J Neurochem. 2012 Jan;120(2):202-9. (PMID: 22043863)
J Natl Cancer Inst. 2015 Aug 20;107(10):null. (PMID: 26293574)
Trends Cell Biol. 2009 Jan;19(1):16-23. (PMID: 19027299)
Neurobiol Dis. 2001 Jun;8(3):405-18. (PMID: 11442350)
Hum Mol Genet. 2000 Nov 22;9(19):2799-809. (PMID: 11092756)
Cancer Res. 2008 Apr 15;68(8):2789-94. (PMID: 18413746)
Neurosci Lett. 2008 Jan 24;431(1):45-50. (PMID: 18078716)
Cell Death Dis. 2014 May 29;5:e1269. (PMID: 24874741)
Mol Neurobiol. 2015 Feb;51(1):406-23. (PMID: 24788684)
Biochem J. 2010 Dec 15;432(3):461-72. (PMID: 20868367)
Hum Pathol. 2008 Nov;39(11):1582-9. (PMID: 18703216)
Open Biol. 2016 Oct;6(10):. (PMID: 27805903)
J Neurosci. 2008 Apr 9;28(15):3947-57. (PMID: 18400894)
Mol Cell. 2003 Jan;11(1):11-23. (PMID: 12535517)
Neuron. 2017 Apr 5;94(1):93-107.e6. (PMID: 28384479)
Acta Neuropathol Commun. 2017 Mar 8;5(1):19. (PMID: 28274274)
Prog Neurobiol. 2007 Nov;83(4):228-48. (PMID: 17467140)
Sci Rep. 2016 Sep 08;6:30238. (PMID: 27605415)
المشرفين على المادة: 0 (14-3-3 Proteins)
0 (Adaptor Proteins, Signal Transducing)
0 (Phosphoproteins)
0 (RNA, Messenger)
0 (Transcription Factors)
0 (YAP-Signaling Proteins)
0 (YAP1 protein, human)
EC 2.7.11.1 (Protein Serine-Threonine Kinases)
تواريخ الأحداث: Date Created: 20180729 Date Completed: 20191016 Latest Revision: 20211204
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC6063913
DOI: 10.1038/s41598-018-29319-4
PMID: 30054496
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-018-29319-4